Study outlines cases of people successfully treating cancer with fenbendazole protocol

At a time when turbo cancers are alarming doctors and patients around the world thanks to the widespread use of risky COVID-19 vaccines, the need for effective cancer treatments has never been more pressing. Although this disease is notoriously difficult to treat, some people are finding success with a treatment known as fenbendazole.

This anti-parasitic drug has been getting some attention for its potential in treating various types of cancer, particularly pancreatic cancer, which is known for being highly aggressive and having a low survival rate. There have been a number of early studies showing that it can be helpful, although further research is needed to reach a more definitive conclusion.

The medication is currently used primarily by vets to treat gastrointestinal parasites in animals, such as hookworms, roundworms and whip worms, but research suggesting that it has the power to inhibit the growth of cancer cells and spur the death of cancer cells by inhibiting glucose uptake and disrupting the formation of microtubules could change the way cancer is treated in the future.

Some people are already trying it out with varying degrees of success. One popular protocol is the Stanford Fenbendazole Protocol. On X, Dr. William Makis shared several examples of the protocol in action taken from a Case Series published by the Department of Medicine at Stanford University Medical Center.

One of the cases involves a 72-year-old man who was suffering from stage 4 cancer of the urethra who developed metastases in the lymph node, brain and lung. After failing a number of treatments, including radiotherapy, pembrolizumab, paclitaxel and carboplatin, not to mention six cycles of cisplatin and gemcitabine, he switched to a regimen of 1000 milligrams of fenbendazole orally three times per week, along with vitamin E, curcumin and CBD oil. A CT scan later showed his tumor shrinking by 2 cm before eventually disappearing entirely.

Another case involved a 63-year-old man who was suffering from stage 4 renal cell carcinoma with metastases to the pancreas and bone and a 5.3 cm mass. Three lines of chemotherapy were unsuccessful, but he was able to reach remission after taking 1000 milligrams of fenbendazole three times a week; his tumors also shrink considerably.

The third case involved a 63-year-old woman who was suffering from stage 4 bladder cancer and had a 7.5 cm tumor. She used chemotherapy and fenbendazole in conjunction with one another, and a follow-up CT found no sign of the disease after treatment.

Makis noted the importance of new treatments as we deal with a “tsunami of cancer,” particularly turbo cancers caused by mRNA vaccines, pointing out that the protocol is largely suppressed by search engines.

“Every cancer patient MUST have an Alternative Treatment approach, which can be taken concurrently with conventional chemotherapy, radiation therapy or immunotherapy, as the Stanford Group showed,” he wrote.

Global cancer deaths to rise by 93% by 2050 among men

A new study that was published in the journal Cancer shows that cancer cases and deaths are expected to surge by the year 2050 among men, especially those aged 65 and older. The study, which was carried out by Australian researchers, projected that the overall cancer cases in men will rise from 10.3 million in 2022 to 19 million in 2054 in a jump of 84%, while deaths from cancer are projected to climb from 5.4 million in 2022 two 10.5 million by 2050 for a rise of 93%. When looking at those older than 65, cancer deaths were projected to rise by 117%.

Sources for this article include:

X.com

Healthline.com

Nature.com

CNN.com